H

oping to deflect criticism of its pricing, Eli Lilly released data showing that rebates and discounts paid to middlemen are increasingly reducing the list prices charged for its drugs.

The drug maker issued a report indicating list prices for its medicines rose a hefty 14 percent last year, but less than the 16.5 percent increase in 2015. However, the average discounts off US list prices rose to 50 percent from 28 percent over the past five years. As a result, Lilly maintained increases in net prices — after paying rebates and discounts — fell to 2.4 percent from 9.4 percent in 2015 (see page 15).

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.

X